Sun Pharma shareholders ratified Cost Auditor remuneration for FY 2025–26 via postal ballot.
Shareholders approved an alteration to the company's Memorandum of Association main objects clause.
Dr Pawan Goenka was re-appointed as Independent Director for a second five-year term.
All resolutions passed with requisite majority and are effective from 17 April 2026.